What Are the Barriers to Biosimilar Uptake in the US?

March 27, 2020

An expert panel discussed the systemic and policy barriers to the uptake of biosimilars.

Many systemic and policy hurdles impede the uptake of biosimilars in the US market, according to a panel of experts who spoke at the Biosimilars: Breaking Through the Barriers symposium earlier this month in Washington, DC.

“Despite the fact that many of us feel sort of tired because we've been doing this for 10, 12 or 15 years, we are at the same time in the beginning of this marketplace,” said panelist, Alex Brill, a resident fellow at the American Enterprise Institute, a conservative think tank based in Washington, DC.

Besides Brill, the panel consisted of Brett Baker, senior health policy advisor on the US Senate Committee on Finance; Wayne Winegarden, director of the Center for Medical Economics and Innovation and a senior fellow at the Pacific Research Institute in San Francisco, California; and Rep Michael C. Burgess, MD, R-Texas.

The panel was co-moderated by Marc Siegel, MD, a Fox News contributor, and Juliana Reed, vice president and global corporate affairs lead for Inflammation and Immunology at Pfizer.

The panelists discussed their commitment to expand biosimilar use in the United States and how physicians and government officials are looking to help.

Visit The Center for Biosimilars for the full story.